FDA Orders Recall of Over 580,000 Bottles of Prazosin

The U.S. Food and Drug Administration (FDA) has announced a significant recall of more than 580,000 bottles of the blood pressure medication prazosin hydrochloride. This action follows concerns that some of the capsules may contain cancer-causing chemicals. The recalls were issued earlier this month by New Jersey-based Teva Pharmaceuticals USA in collaboration with drug distributor Amerisource Health Services.

Prazosin is primarily prescribed to relax blood vessels and help lower blood pressure. It is also used to treat nightmares and other sleep disturbances linked to post-traumatic stress disorder. The FDA has classified the affected lots as Class II risk, indicating that while the risk is not the highest, there is a potential for serious adverse effects.

According to the FDA’s enforcement orders, the concerns about the medication stem from the presence of N-nitrosamine impurities. These impurities can form during the manufacturing or storage processes of drugs and are classified as potentially cancer-causing substances. The FDA has emphasized the importance of addressing this issue to ensure patient safety.

Patients who are in possession of the recalled medication are advised to consult their healthcare providers for alternatives and to return the affected products to their pharmacies. Teva Pharmaceuticals has committed to addressing the situation promptly and ensuring that all necessary steps are taken to safeguard public health.

This recall highlights ongoing concerns regarding drug safety and the potential presence of harmful substances in pharmaceuticals. As regulatory bodies like the FDA continue to monitor such issues, patients are encouraged to stay informed and proactive about their medication safety.